Verona Pharma Plc ADR (NASDAQ:VRNA) shares, rose in value on Friday, March 28, with the stock price down by -2.81% to the previous day’s close as strong demand from buyers drove the stock to $62.70.
Actively observing the price movement in the last trading, the stock closed the session at $64.51, falling within a range of $62.0 and $64.414. The value of beta (5-year monthly) was 0.393. Referring to stock’s 52-week performance, its high was $70.40, and the low was $11.39. On the whole, VRNA has fluctuated by -6.59% over the past month.
With the market capitalization of Verona Pharma Plc ADR currently standing at about $5.31 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-26.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 243.22M, with a low estimate of 33.5M and a high estimate of 53.2M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 41.47M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that VRNA’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of VRNA currently trading nearly -3.78% and 1.15% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 47.10, while the 7-day volatility ratio is showing 4.03% which for the 30-day chart, stands at 5.50%. Furthermore, Verona Pharma Plc ADR (VRNA)’s beta value is 0.14, and its average true range (ATR) is 3.28.
A comparison of Verona Pharma Plc ADR (VRNA) with its peers suggests the former has fared considerably weaker in the market. VRNA showed an intraday change of -2.81% in last session, and over the past year, it grew by 288.48%%.
Data on historical trading for Verona Pharma Plc ADR (NASDAQ:VRNA) indicates that the trading volumes over the past 10 days have averaged 0.9 and over the past 3 months, they’ve averaged 1.43 million. According to company’s latest data on outstanding shares, there are 84.63 million shares outstanding.
Nearly 12.31% of Verona Pharma Plc ADR’s shares belong to company insiders and institutional investors own 69.60% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 9.85 million shares as on 2025-03-14, resulting in a short ratio of 6.25. According to the data, the short interest in Verona Pharma Plc ADR (VRNA) stood at 1208.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 7.78 million. The stock has risen by 35.01% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VRNA stock heading into the next quarter.
